Display options
Cite
Aye MM, Atkin SL. Patient safety and minimizing risk with insulin administration - role of insulin degludec. Drug Healthc Patient Saf. 2014;6:55-67doi: 10.2147/DHPS.S59566.
Aye, M. M., & Atkin, S. L. (2014). Patient safety and minimizing risk with insulin administration - role of insulin degludec. Drug, healthcare and patient safety, 655-67. https://doi.org/10.2147/DHPS.S59566
Aye, Myint M, and Atkin, Stephen L. "Patient safety and minimizing risk with insulin administration - role of insulin degludec." Drug, healthcare and patient safety vol. 6 (2014): 55-67. doi: https://doi.org/10.2147/DHPS.S59566
Aye MM, Atkin SL. Patient safety and minimizing risk with insulin administration - role of insulin degludec. Drug Healthc Patient Saf. 2014 Apr 30;6:55-67. doi: 10.2147/DHPS.S59566. eCollection 2014. PMID: 24812526; PMCID: PMC4010638.
Copy Download .nbib Format: NLM
Share it on

Drug Healthc Patient Saf. 2014 Apr 30;6:55-67. doi: 10.2147/DHPS.S59566. eCollection 2014.

Patient safety and minimizing risk with insulin administration - role of insulin degludec.

Drug, healthcare and patient safety

Myint M Aye, Stephen L Atkin

Affiliations

  1. Hull Royal Infirmary, Michael White Diabetes Centre, Hull, UK.
  2. Weill Cornell Medical College Qatar, Qatar Foundation, Doha, Qatar.

PMID: 24812526 PMCID: PMC4010638 DOI: 10.2147/DHPS.S59566

Abstract

Diabetes is a lifelong condition requiring ongoing medical care and patient self-management. Exogenous insulin therapy is essential in type 1 diabetes and becomes a necessity in patients with longstanding type 2 diabetes who fail to achieve optimal control with lifestyle modification, oral agents, and glucagon-like peptide 1-based therapy. One of the risks that hinders insulin use is hypoglycemia. Optimal insulin therapy should therefore minimize the risk of hypoglycemia while improving glycemic control. Insulin degludec (IDeg) is a novel basal insulin that, following subcutaneous injection, assembles into a depot of soluble multihexamer chains. These subsequently release IDeg monomers that are absorbed at a slow and steady rate into the circulation, with the terminal half-life of IDeg being ~25 hours. Thus, it requires only once-daily dosing unlike other basal insulin preparations that often require twice-daily dosing. Despite its long half-life, once-daily IDeg does not cause accumulation of insulin in the circulation after reaching steady state. IDeg once a day will produce a steady-state profile with a lower peak:trough ratio than other basal insulins. In clinical trials, this profile translates into a lower frequency of nocturnal hypoglycemia compared with insulin glargine, as well as an ability to allow some flexibility in dose timing without compromising efficacy and safety. Indeed, a study that tested the extremes of dosing intervals of 8 and 40 hours showed no detriment in either glycemic control or hypoglycemic frequency versus insulin glargine given at the same time each day. While extreme flexibility in dose timing is not recommended, these findings are reassuring. This may be particularly beneficial to elderly patients, patients with learning difficulties, or others who have to rely on health-care professionals for their daily insulin injections. Further studies are required to confirm whether this might benefit adherence to treatment, reduce long-term hypoglycemia or reduce diabetes-related complications.

Keywords: basal insulin; diabetes; hypoglycemia; safety

References

  1. Drugs Aging. 2013 Dec;30(12):1009-18 - PubMed
  2. Prim Care Diabetes. 2009 Aug;3(3):131-9 - PubMed
  3. Diabet Med. 2013 Mar;30(3):e115-22 - PubMed
  4. Am J Manag Care. 2011 Oct;17(10):673-80 - PubMed
  5. Diabetologia. 2002 Jul;45(7):937-48 - PubMed
  6. Arch Intern Med. 1997 Aug 11-25;157(15):1681-6 - PubMed
  7. Nat Rev Endocrinol. 2012 Feb 28;8(7):425-33 - PubMed
  8. Diabet Med. 2005 Jun;22(6):749-55 - PubMed
  9. Diabetes Care. 2013 Jan;36 Suppl 1:S11-66 - PubMed
  10. J Affect Disord. 2012 Oct;142 Suppl:S8-21 - PubMed
  11. Diabetes Care. 2003 Jun;26(6):1902-12 - PubMed
  12. JAMA. 2003 May 7;289(17):2254-64 - PubMed
  13. Diabetes Care. 2013 Apr;36(4):858-64 - PubMed
  14. J Clin Endocrinol Metab. 2013 Mar;98(3):1154-62 - PubMed
  15. Diabetes Obes Metab. 2012 Oct;14(10):944-50 - PubMed
  16. BMJ. 2013 Jul 29;347:f4533 - PubMed
  17. Diabetes. 2004 Jun;53(6):1614-20 - PubMed
  18. Diabetologia. 2005 Oct;48(10):1988-95 - PubMed
  19. Drugs Aging. 2014 Jan;31(1):47-53 - PubMed
  20. Lancet Diabetes Endocrinol. 2013 Oct;1(2):123-31 - PubMed
  21. Clin Drug Investig. 2014 Feb;34(2):127-33 - PubMed
  22. Diabetes Obes Metab. 2014 Jun;16(6):483-91 - PubMed
  23. Diabetes Obes Metab. 2009 Nov;11 Suppl 5:1-5 - PubMed
  24. N Engl J Med. 2005 Jan 13;352(2):174-83 - PubMed
  25. J Clin Endocrinol Metab. 2010 May;95(5):2240-7 - PubMed
  26. Diabetes Technol Ther. 2011 Jun;13 Suppl 1:S103-8 - PubMed
  27. Diabetes Care. 2013 Sep;36(9):2536-42 - PubMed
  28. J Clin Invest. 1976 Jul;58(1):7-15 - PubMed
  29. Clin Drug Investig. 2013 Jul;33(7):515-21 - PubMed
  30. Diabetes Obes Metab. 2012 Sep;14(9):859-64 - PubMed
  31. Diabet Med. 2008 Mar;25(3):245-54 - PubMed
  32. Diabetes Care. 2012 Jun;35(6):1364-79 - PubMed
  33. Diabetes Obes Metab. 2013 Feb;15(2):175-84 - PubMed
  34. Diabetes Obes Metab. 2007 Sep;9(5):648-59 - PubMed
  35. JAMA Intern Med. 2013 Jul 22;173(14):1300-6 - PubMed
  36. Clin Pharmacokinet. 2014 Feb;53(2):175-83 - PubMed
  37. Lancet. 2012 Apr 21;379(9825):1498-507 - PubMed
  38. Lancet. 2012 Apr 21;379(9825):1489-97 - PubMed
  39. Diabetes. 2002 Mar;51(3):724-33 - PubMed
  40. Diabetes Care. 2012 Dec;35(12):2464-71 - PubMed
  41. Diabetes Care. 2005 May;28(5):1245-9 - PubMed
  42. Ann Fam Med. 2013 May-Jun;11(3):245-50 - PubMed
  43. Pharm Res. 2012 Aug;29(8):2104-14 - PubMed
  44. Endocr Pract. 2014 Jan;20(1):75-83 - PubMed
  45. Diabet Med. 2012 May;29(5):682-9 - PubMed
  46. J Am Geriatr Soc. 1966 May;14(5):463-71 - PubMed
  47. N Engl J Med. 1988 May 12;318(19):1231-9 - PubMed
  48. Drugs Aging. 2004;21(8):511-30 - PubMed
  49. J Diabetes Investig. 2013 Nov 27;4(6):605-12 - PubMed
  50. Diabetes Metab Res Rev. 2007 Sep;23(6):441-54 - PubMed
  51. Diabetes Obes Metab. 2013 Sep;15 Suppl 3:98-104 - PubMed

Publication Types